News | May 27, 2007

AccessClosure’s Mynx Uses Hydrogel to Close Cath Site

May 29, 2007 — The FDA has cleared the Mynx VCS vascular closure system (VCD) by AccessClosure designed to seal a puncture site in the femoral artery and stop the bleeding after a cardiac catheterization procedure.

The Mynx VCS uses a balloon catheter and a standard procedural sheath to deliver an extravascular, hydrogel sealant used to seal the puncture site. Following the cardiac catheterization procedure, the Mynx VCS balloon catheter is inserted through the introducer sheath into the femoral artery to temporarily stop bleeding at the puncture site.

The hydrogel sealant is injected through the introducer sheath at the puncture site and within the tissue tract that stops the bleeding and seals the access site. Once sealed, the balloon catheter is deflated and removed along with the introducer sheath and manual compression is applied for one to two minutes to ensure bleeding stops. The gel will absorb into the body within 30 days.

The Mynx is used on patients who have undergone diagnostic or interventional endovascular procedures, and is indicated for use to seal femoral arterial access sites while reducing times to hemostasis and ambulation utilizing a 5F, 6F or 7F procedural sheath.

For more information visit www.fda.gov/cdrh/pdf4/p040044s001.html, and www.fda.gov/hearthealth.

Related Content

Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial
News | Vascular Closure Devices | May 10, 2018
Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the...
Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial
News | Vascular Closure Devices | February 21, 2018
Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional...
The bioresorbable Cordis Mynx Grip vascular closure device seals arteriotomies without use of permanent hardware.

The bioresorbable Cordis MynxGrip vascular closure device seals arteriotomies without use of permanent hardware.

Feature | Vascular Closure Devices | January 22, 2018 | Dave Fornell
While manual compression remains the gold standard for hemostasis of catheterization vascular access site arteriotomi
Vivasure Enrolls First Patient in Frontier IV Clinical Trial
News | Vascular Closure Devices | December 29, 2017
Vivasure Medical announced in October the successful enrollment of the first patient in the Frontier IV clinical study...
Enrollment Completed in U.S. IDE Trial for Manta Large Bore Vascular Closure Device
News | Vascular Closure Devices | December 22, 2017
Essential Medical announced the completion of enrollment in the U.S. pivotal investigational device exemption (IDE)...
Vasorum Launches Celt ACD Second-Generation Vascular Closure Device in the U.S.
Technology | Vascular Closure Devices | December 14, 2017
Vasorum Ltd, the developer and manufacturer of the novel Celt ACD vascular closure device, has added a 7F-sized Celt...
angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices | October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
Vivasure Medical, Closure Device, Series C financing
News | Vascular Closure Devices | September 12, 2016
September 12, 2016 — Vivasure Medical announced last week that the company has completed a Series C financing of €16.
Overlay Init